AERIE PHARMACEUTICALS INC (AERI) [Rocket]

Date Filed	Type	Description
12/04/2018	GN	Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
08/16/2018	GN	Factors of Influence in 2018, Key Indicators and Opportunity within inTest, Hooker Furniture, American Public Education, Gevo, Envestnet, and Aerie Pharmaceuticals — New Research Emphasizes Economic Growth
05/08/2018	BW	Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
04/26/2018	BW	Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
03/21/2018	GN	Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics — Discovering Underlying Factors of Influence
03/21/2018	BW	Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
02/28/2018	BW	Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
02/21/2018	BW	Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
11/08/2017	BW	Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
11/07/2017	BW	Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
11/01/2017	BW	Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
09/11/2017	GN	Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) to Ring The Nasdaq Stock Market Closing Bell
09/06/2017	BW	Aerie Pharmaceuticals to Present at Two Investor Conferences in September
08/01/2017	BW	Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
07/26/2017	BW	Aerie Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
07/19/2017	BW	Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
06/01/2017	BW	Aerie Pharmaceuticals to Present at Two Investor Conferences in June
05/02/2017	BW	Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
04/25/2017	BW	Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017